Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma
ObjectivesMaintenance therapy with capecitabine after induction chemotherapy for patients with newly diagnosed metastatic nasopharyngeal carcinoma (mNPC) has been confirmed to be effective. This study aimed to evaluate the cost-effectiveness of capecitabine as maintenance therapy for patients with m...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2022.1086393/full |
| _version_ | 1797942744725848064 |
|---|---|
| author | Jiaqi Han Xiaomeng Lan Kun Tian Xi Shen Jinlan He Nianyong Chen |
| author_facet | Jiaqi Han Xiaomeng Lan Kun Tian Xi Shen Jinlan He Nianyong Chen |
| author_sort | Jiaqi Han |
| collection | DOAJ |
| description | ObjectivesMaintenance therapy with capecitabine after induction chemotherapy for patients with newly diagnosed metastatic nasopharyngeal carcinoma (mNPC) has been confirmed to be effective. This study aimed to evaluate the cost-effectiveness of capecitabine as maintenance therapy for patients with mNPC from the Chinese payers' perspective.MethodsMarkov model was conducted to simulate the disease progress and evaluated the economic and health outcomes of capecitabine maintenance plus best-supported care (CBSC) or best-supported care (BSC) alone for patients with mNPC. Survival data were derived from the NCT02460419 clinical trial. Costs and utilities were obtained from the standard fee database and published literature. Measured outcomes were total costs, quality-adjusted life-years (QALYs), life-years (LYs), incremental cost-utility ratios (ICURs), incremental cost-effectiveness ratios (ICERs), incremental net monetary benefit (INMB), and incremental net-health benefit (INHB). Sensitivity analyses were performed to assess model robustness. Additional subgroup cost-effectiveness analyses were accomplished.ResultsThroughout the course of the disease, the CBSC group provide an incremental cost of $9 734 and additional 1.16 QALYs (1.56 LYs) compared with the BSC group, resulting in an ICUR of $8 391/QALY and ICER of $6 240/LY. Moreover, the INHB was 0.89 QALYs, and the INMB was $32 034 at the willingness-to-pay threshold of $36 007/QALY. Subgroup analyses revealed that CBSC presented a positive trend of gaining an INHB in all subgroups compared with the BSC group. The results of sensitivity analyses supported the robustness of our model.ConclusionCompared with BSC, after induction chemotherapy, CBSC as a first-line treatment was cost-effective for newly diagnosed mNPC. These results suggest capecitabine maintenance therapy after induction chemotherapy as a new option for patients with newly diagnosed mNPC. |
| first_indexed | 2024-04-10T20:13:06Z |
| format | Article |
| id | doaj.art-105a90fe9ce64be6851a9cf45eceee13 |
| institution | Directory Open Access Journal |
| issn | 2296-2565 |
| language | English |
| last_indexed | 2024-04-10T20:13:06Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Public Health |
| spelling | doaj.art-105a90fe9ce64be6851a9cf45eceee132023-01-26T08:35:12ZengFrontiers Media S.A.Frontiers in Public Health2296-25652023-01-011010.3389/fpubh.2022.10863931086393Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinomaJiaqi Han0Xiaomeng Lan1Kun Tian2Xi Shen3Jinlan He4Nianyong Chen5Department of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and Laboratory of Single Cell Research and Liquid Biopsy, West China Hospital, Sichuan University, Chengdu, ChinaWest China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, ChinaDepartment of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and Laboratory of Single Cell Research and Liquid Biopsy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and Laboratory of Single Cell Research and Liquid Biopsy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and Laboratory of Single Cell Research and Liquid Biopsy, West China Hospital, Sichuan University, Chengdu, ChinaObjectivesMaintenance therapy with capecitabine after induction chemotherapy for patients with newly diagnosed metastatic nasopharyngeal carcinoma (mNPC) has been confirmed to be effective. This study aimed to evaluate the cost-effectiveness of capecitabine as maintenance therapy for patients with mNPC from the Chinese payers' perspective.MethodsMarkov model was conducted to simulate the disease progress and evaluated the economic and health outcomes of capecitabine maintenance plus best-supported care (CBSC) or best-supported care (BSC) alone for patients with mNPC. Survival data were derived from the NCT02460419 clinical trial. Costs and utilities were obtained from the standard fee database and published literature. Measured outcomes were total costs, quality-adjusted life-years (QALYs), life-years (LYs), incremental cost-utility ratios (ICURs), incremental cost-effectiveness ratios (ICERs), incremental net monetary benefit (INMB), and incremental net-health benefit (INHB). Sensitivity analyses were performed to assess model robustness. Additional subgroup cost-effectiveness analyses were accomplished.ResultsThroughout the course of the disease, the CBSC group provide an incremental cost of $9 734 and additional 1.16 QALYs (1.56 LYs) compared with the BSC group, resulting in an ICUR of $8 391/QALY and ICER of $6 240/LY. Moreover, the INHB was 0.89 QALYs, and the INMB was $32 034 at the willingness-to-pay threshold of $36 007/QALY. Subgroup analyses revealed that CBSC presented a positive trend of gaining an INHB in all subgroups compared with the BSC group. The results of sensitivity analyses supported the robustness of our model.ConclusionCompared with BSC, after induction chemotherapy, CBSC as a first-line treatment was cost-effective for newly diagnosed mNPC. These results suggest capecitabine maintenance therapy after induction chemotherapy as a new option for patients with newly diagnosed mNPC.https://www.frontiersin.org/articles/10.3389/fpubh.2022.1086393/fullnasopharyngeal carcinomacost-effectivenesscapecitabinemaintenance therapyreal-world data |
| spellingShingle | Jiaqi Han Xiaomeng Lan Kun Tian Xi Shen Jinlan He Nianyong Chen Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma Frontiers in Public Health nasopharyngeal carcinoma cost-effectiveness capecitabine maintenance therapy real-world data |
| title | Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma |
| title_full | Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma |
| title_fullStr | Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma |
| title_full_unstemmed | Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma |
| title_short | Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma |
| title_sort | cost effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs best supportive care alone as first line treatment of newly diagnosed metastatic nasopharyngeal carcinoma |
| topic | nasopharyngeal carcinoma cost-effectiveness capecitabine maintenance therapy real-world data |
| url | https://www.frontiersin.org/articles/10.3389/fpubh.2022.1086393/full |
| work_keys_str_mv | AT jiaqihan costeffectivenessanalysisofcapecitabinemaintenancetherapyplusbestsupportivecarevsbestsupportivecarealoneasfirstlinetreatmentofnewlydiagnosedmetastaticnasopharyngealcarcinoma AT xiaomenglan costeffectivenessanalysisofcapecitabinemaintenancetherapyplusbestsupportivecarevsbestsupportivecarealoneasfirstlinetreatmentofnewlydiagnosedmetastaticnasopharyngealcarcinoma AT kuntian costeffectivenessanalysisofcapecitabinemaintenancetherapyplusbestsupportivecarevsbestsupportivecarealoneasfirstlinetreatmentofnewlydiagnosedmetastaticnasopharyngealcarcinoma AT xishen costeffectivenessanalysisofcapecitabinemaintenancetherapyplusbestsupportivecarevsbestsupportivecarealoneasfirstlinetreatmentofnewlydiagnosedmetastaticnasopharyngealcarcinoma AT jinlanhe costeffectivenessanalysisofcapecitabinemaintenancetherapyplusbestsupportivecarevsbestsupportivecarealoneasfirstlinetreatmentofnewlydiagnosedmetastaticnasopharyngealcarcinoma AT nianyongchen costeffectivenessanalysisofcapecitabinemaintenancetherapyplusbestsupportivecarevsbestsupportivecarealoneasfirstlinetreatmentofnewlydiagnosedmetastaticnasopharyngealcarcinoma |